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INTRODUCTION
============

Cervical cancer (CC) remains as one of the major health problems in developing countries. Estimated mortality for CC in Mexico in 2000 was 17.1/100,000 (1, 19). Human papillomavirus (HPV) is the main causal factor of CC, but there are other risk factors that contribute to the development of CC such as smoking, multiple pregnancies, oral contraceptive use, family history of CC, high viral load and low socioeconomic status (2, 9).

Overall prevalence of HPV infection among women with normal cytology worldwide is estimated to be 10.5% (6); however, HPV prevalence varied nearly 20 times among different populations, from 1.4% in Spain to 25.6% in Nigeria (5).

More than 40 HPV types infect the human anogenital tract (7). HPV types are classified into low or high risk on the basis of their association with premalignant and malignant lesions (23). In this regard, HPV type 16 is involved in ?54% of all cases of invasive CC worldwide, whereas HPV type 18 causes about 11% of all cases (15). Other HPV genotypes are less frequently associated with cancer. HPV types 16, 18, 31, 45, 53 and 58 have frequently been found in cervical samples of Mexican women (14, 16, 17, 22). Little is known regarding HPV prevalence in women with and without CC in different Mexican populations. The obtained prevalence varied depending on the study. In cancer samples, HPV was detected in 87−92% of samples. High-grade squamous intraepithelial lesions (HGSIL) were detected in 29.4−88% of samples, and low-grade squamous intraepithelial lesions (LGSIL) were detected in 24−57% of samples and in normal smears in 12−17% of samples (3, 16, 22). The general prevalence of HPV in women from the city of Durango (located in northern Mexico) was estimated at 4.8% (17), but a higher prevalence (20.4%) was reported for HPV in the state of Morelos (14). Lazcano-Ponce et al. (14) found a prevalence of 16.7% in Mexican women \<25 years of age, which decreased to 3.7% in women 25−44 years of age and increased to 23% in women \>65 years of age. Little information exists about HPV in rural and suburban regions of the country, and little is known about the molecular epidemiology of HPV in the state of Tlaxcala, Mexico. In the present study we determined the prevalence of HPV genotypes 6, 11, 16, 18 and 31 in women treated at a General Hospital in Tlaxcala, which is also situated in the central region of Mexico and is one of the poorest states in Mexico.

MATERIALS AND METHODS
=====================

Study population
----------------

We studied women requesting cervical Papanicolaou examination at the General Hospital Zone No. 1 of the Mexican Institute of Social Security (IMSS) in Tlaxcala, Mexico. All participants were enrolled consecutively from November 2006 to May 2008.

A total of 236 samples were analyzed. Patient data such as age, residence, age at first sexual intercourse, number of sexual partners and number of pregnancies were also collected from a questionnaire. The study was approved by the institutional ethics committee. The purpose and procedures of the study were explained to patients, and informed consent was obtained from all participants.

Collection of specimens
-----------------------

Two cervical samples were obtained from each patient using a cytobrush. The first sample was used for cytological diagnosis. Papanicolaou smears were evaluated by a pathologist according to the Bethesda diagnostic criteria (18). The second sample was used to detect HPV by PCR. In addition to Pap smear, each woman had colposcopy and, when necessary, a biopsy was obtained for pathological diagnosis. No biopsy was obtained for research purposes.

DNA extraction
--------------

Cervical smears were placed in tubes containing 5 ml phosphate-buffered saline (PBS), vigorously shaken, and centrifuged for 10 min at 4000 × g. Pellets were resuspended in 1 ml PBS, and a 0.5-ml aliquot was used for DNA extraction using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Purified DNA was suspended in 100 οl of water and stored at −20^o^C until use. All samples were tested for integrity of DNA by 1% agarose gel electrophoresis.

PCR assays
----------

Detection of HPV genotypes 6, 11, 16, 18, and 31 was carried out using primer-specific PCR (21). Amplification reactions containing a final volume of 25 οl were performed with Taq PCR Master Mix Kit (Promega, Madison, WI), 0.2 οM concentration of each primer and 10.5 οl of DNA sample. Forty amplification cycles were performed with a thermocycler (PTC 200, MJ Research, Watertown, MA). Each cycle consisted of a denaturing step at 95°C for 1 min followed by a primer annealing step for 1 min at 55°C for HPV types 16 and 31 or at 60°C for HPV types 6, 11 and 18, and a chain elongation step at 72°C for 1 min. Finally, 15 οl of the amplification product was analyzed by 1.5% agarose gel electrophoresis. A fragment of the cyclophilin gene was amplified as internal control (24). Gels were stained with ethidium bromide (1 μg/ml), observed with an ultraviolet transilluminator, and photographed using a digital camera (DC290, Kodak, Rochester, NY).

Statistical analysis
--------------------

Frequencies of clinical data were calculated. Differences between groups were calculated by χ^2^ test; *p* \<0.05 was considered significant. Data were analyzed using SPSS for Windows, v.12 (Chicago, IL).

RESULTS
=======

Study population
----------------

A total of 236 cervical specimens were analyzed for cytological diagnosis and HPV detection. LGSIL was diagnosed in 97 (41.1%) cases, HGSIL in 39 (16.5%) cases and normal cervical smears in 100 cases (42.4%).

Prevalence of HPV types
-----------------------

Overall prevalence of HPV in the studied population was 31.3%. HPV was detected in 22/100 (22%) samples with normal cytology, 36/39 (37%) samples with LGSIL and 16/39 (41%) samples with HGSIL ([Table 1](#tbl1){ref-type="table"}).

HPV 16 and 18 were found in 34/74 (45.9%) and 23/74 (31.1%) infected samples, respectively (including co-infections). The prevalence of HPV types 31, 6 and 11 were 16.2%, 10.8% and 6.7%, respectively.

Infections with mixtures of two genotypes were detected in 8/74 (10.8%) HPV-positive samples; 6/8 coinfections involved HPV type 16, and 5/8 involved HPV type 18 ([Table 2](#tbl2){ref-type="table"}). Mixtures of low-risk HPV genotypes were not observed. Multiple infections with different viral genotypes were detected in the three groups (normal, LGSIL and HGSIL).

HPV 16 was found in 9/100 (9%) normal samples, 17/97 (17.5%) samples with LGSIL and 8/39 (20.5%) samples with HGSIL ([Table 3](#tbl3){ref-type="table"}). HPV 18 was found in 9/100 normal samples, 12/97 (12.4%) samples with LGSIL and 2/39 (5.1%) samples with HGSIL.

###### 

Prevalence of HPV in women from Tlaxcala, Mexico

  **Cytological diagnosis**                **Samples *n***   **Positive samples *n***   **Prevalence %(95% CI)**
  ---------------------------------------- ----------------- -------------------------- --------------------------
  Normal[a](#tf1-1){ref-type="table-fn"}   100               22                         22 (17.8−26.2)
  LGSIL                                    97                36                         37.1 (29.82−44.38)
  HGSIL                                    39                16                         41 (28.3−53.7)
  Total                                    236               74                         31.3 (27.4−35.2)

Samples were classified as normal if they did not present alterations either at cytology or colposcopy.

LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-grade squamous intraepithelial lesion.

###### 

HPV co-infections in cervical samples

  **Diagnosis**   **Number of samples presenting mixtures of HPV genotypes**                   
  --------------- ------------------------------------------------------------ --- --- --- --- ---
  Normal          1                                                            0   1   0   0   0
  LGSIL           5                                                            1   1   1   1   1
  HGSIL           2                                                            1   1   0   0   0
  Total           8                                                            2   3   1   1   1

###### 

Prevalence of HPV genotypes in women from Tlaxcala, Mexico

  **Cytological diagnosis**        **HPV 16**                                                **HPV 18**                                              **HPV31**                                             **HPV 6**                                             **HPV 11**
  --------------------------- ---- ---------------------------------------------------- ---- -------------------------------------------------- ---- ------------------------------------------------- --- ------------------------------------------------- --- -------------------------------------------------
  Normal                      9    9 (7.3−10.7)                                         9    9 (7.3−10.7)                                       1    1                                                 1   1                                                 3   3 (2.5−3.5)
  LGSIL                       17   17.5 (14.1−20.9)                                     12   12.4 (10.0−14.8)                                   7    7.2 (6.5−7.9)                                     3   3.1 (5.9−8.5)                                     2   2.1 (1.8−2.4)
  HGSIL                       8    20.5 (14.2−26.8)                                     2    5.1 (3.7-6.5)                                      4    10.2 (7.2-13.2)                                   4   10.2 (7.2-13.2)                                   0   0
  Total                       34   14.4[^b^](#tf3-2){ref-type="table-fn"} (12.6−16.2)   23   9.7[^b^](#tf3-2){ref-type="table-fn"} (8.5-10.9)   12   5.1[^b^](#tf3-2){ref-type="table-fn"} (4.5−5.7)   8   3.4[^b^](#tf3-2){ref-type="table-fn"} (3.0−3.8)   5   2.1[^b^](#tf3-2){ref-type="table-fn"} (1.9−2.3)

Samples were classified as normal if they did not present alterations either at cytology or colposcopy.

Results included co-infections.

Age-specific HPV prevalence
---------------------------

Mean age of women enrolled in this study was 37.8 years (range: 18−74 years). Mean age of women with HGSIL was 41.7 years, LGSIL 36.5 years, and normal cytology 37.7 years. There was no statistical difference between age and lesion grade.

Patients were stratified into age groups as follow: 18−24 years (23 samples), 25−34 years (82 samples), 35−44 years (67 samples), 45−54 years (42 samples) and \>55 years (19 samples). General prevalence of HPV for each age group was 43.5%, 31.7%, 35.8%, 19% and 26.3%, respectively ([Fig. 1a](#fig1){ref-type="fig"}).

Distribution of HPV type 16 according to the age of the patients was 5/23 (21.7%) in the 18- to 24-year-old group, 13/82 (15.8%) in the 25- to 34-year-old group, 12/67 (17.9%) in the 35- to 44-year-old group, 1/42 (2.4%) in the 45- to 54-year-old group and 4/19 (21%) in the group \>55 years old ([Fig. 1b](#fig1){ref-type="fig"}). This type of age prevalence distribution with two peaks was observed for HPV 16 but not for HPV 31, HPV 6 and HPV11 (data not shown).

Women infected with high-risk HPV types presented an average age higher (41.4 years) than women with low-risk HPV types (33.4 years), but the statistical analysis was not significant.

Cervical lesions and clinical variables
---------------------------------------

Mean age of first intercourse of all the women enrolled in the study was 19.3 years (range: 12−32 years). Mean age of first intercourse in the HGSIL group (18.5 years) was similar to that of the normal group (19.4 years). We did not find statistical differences between age of first intercourse and grade of cervical neoplasia.

Women in the study had a mean of 2.7 pregnancies. We did not find an association between positive history of multiple pregnancies and grade of neoplasia ([Table 4](#tbl4){ref-type="table"}).

![Age-specific prevalence of HPV.](bjm-41-749-g001){#fig1}

###### 

Risk factors for cervical cancer among normal, LGSIL and HGSIL groups

  **Risk factor**                           **Normal cytology**   **LGSIL**     **HGSIL**
  ----------------------------------------- --------------------- ------------- -------------
  Age (years)                                                                   
  ≤20                                       1%                    3.2%          0
  21−30                                     25%                   31.6%         21.1%
  31−40                                     39%                   34.7%         28.9%
  41−50                                     23%                   18.9%         31.6%
  51−60                                     9%                    9.5%          7.9%
  ≥61                                       3%                    2.1%          10.5%
  Mean ± SD                                 37.7 ± 10.4           36.6 ± 10.8   41.8 ± 12.3
  Age at first sexual intercourse (years)                                       
  ≤18 years                                 41.9%                 49%           58.3%
  ≥19 years                                 58.1%                 51%           41.7%
  Mean ± SD                                 19.4 ± 3.4            19.5 ± 4.2    18.5 ± 4.2
  Number of sexual partners                                                     
  1−2                                       93.1%                 82.6%         88.2%
  +3                                        6.9%                  17.4%         11.8%
  Mean ± SD                                 1.3 ± 0.7             1.8 ± 1.4     1.7 ± 1.3
  Number of pregnancies                                                         
  0                                         7.2%                  9.4%          5.4%
  1−2                                       42.3%                 51%           43.2%
  3+                                        50.5%                 39.6%         51.3%
  Mean ± SD                                 2.7 ± 1.6             2.7 ± 1.8     3.3 ± 2.8

DISCUSSION
==========

The objective of this study was to determine the prevalence of HPV genotypes in Mexican women treated at the General Hospital of Tlaxcala, Mexico, a densely populated and characteristically rural municipality.

HPV prevalence in women with normal cytology was estimated to be 10.4% worldwide, whereas the corresponding estimate in Central America and Mexico was 20.4% (6). Some reports showed significant variations among different regions of Mexico, finding the lowest prevalence (4.8%) in the city of Durango located in northern Mexico with a low population density (PD) 49 p/km^2^ and the highest prevalence (17%) in the metropolitan area of Mexico City (PD 7815 p/km^2^) (13, 17). We found an overall HPV prevalence of 31.3% in women treated at the General Hospital, Tlaxcala, with 22% in women with normal cervical cytology. This represents a higher prevalence of HPV infection with regard to other similar studies (16, 17). In a similar study conducted with women living in a rural zone in Puebla, which is located ∼100 km from Tlaxcala, we found a lower general HPV prevalence (20%) with 14.7% in women with normal cytology (22). We expected to obtain comparable prevalence values in these studies because both involved women residing in rural zones and women who were treated at a general hospital. However, the higher HPV prevalence in Tlaxcala may reflect a limited infrastructure for health services, combined with a higher human population density; Tlaxcala municipality has 1597 p/km^2^ vs. Atlixco municipality, which has 532 p/km^2^ (10, 11).

Sexual behavior in men in the development of cervical cancer has been identified as having a role as a potential risk factor. Especially among high-risk populations, the prevalence of HPV DNA in the penises of husbands of women with CC is very high. The socioeconomic status of the families in Tlaxcala increases the migration of men to the U.S. in order to seek work and obtain an income. This may have a repercussion in the acquisition of sexually transmitted diseases by women, including HPV, when their partners return.

HPV types 16, 18, 31, 58 and 52 represent \>50% of all HPV infections worldwide (6). In our study we searched for the presence of high-risk types 16, 18, and 31 and the low-risk types 6 and 11 due to their importance and frequency.

HPV 16 is the most prevalent type worldwide with the exception of eastern Africa, Japan and Taiwan where the most common type is HPV 52 (6). The prevalence of HPV 16 found in this study (45.9%) is high but consistent with that of other studies reporting a prevalence of 34.7−59.6% for this virus type (2). As expected, HPV 18 was determined to be the second most prevalent genotype (31.1%).

It is noteworthy that women with normal cytology had a higher rate of HPV 18 infection than in other states in Mexico (15, 17). These results must be interpreted with caution because we analyzed a biased population. In fact, the women in our study were treated at a dysplasia clinic; therefore, the prevalence of squamous intraepithelial lesions and HPV is higher than in an open population. Concurrent infection with more than one HPV genotype was found in 10.8% of the analyzed population. This value is in the range observed for multiple infections among different studies (4, 8, 12, 20, 22). Simultaneous infections have been frequently observed among younger women (4). However, in this and in our previous study (22), the mean age of women with multiple infections was ∼45 years (range: 26−63 years).

Age-specific HPV prevalence has been estimated in different studies worldwide. HPV infection characteristically peaks soon after initiation of sexual activity, usually among women in their early twenties. After the age of 25 years, HPV prevalence is higher in less-developed countries than in developed countries, but both showed a continuous decline with increasing age until 45−54 years of age when estimates increased in both regions (6, 12). We found a peak in the 18- to 24-year-old group and a decrease in prevalence until the 55- to 64-year-old group where we found a small second peak of prevalence.

Lazcano-Ponce et al. (14) evaluated the correlation between patients' age and HPV prevalence in Mexican women. A peak of 16.7% was found in the group of \<25-year-old women. Values decreased to 3.7% in the 25- to 44-year-old group and increased to 23% in the group \>65 years of age. In our study the highest HPV prevalence was found in the 18- to 24-year-old group (10/23, 43.5%), and the lowest prevalence (8/42, 19%) was found in the 45- to 54-year-old group.

When we analyzed age-specific HPV prevalence of each HPV type, we found that HPV 16 predominated among all age groups with values from 15−21%, except for the 45- to 54-year-old group who showed a very low prevalence (2.4%). Low-risk HPV types and HPV 31 did not show this second peak. HPV 16 may demonstrate a different behavior than low-risk HPVs and HPV 31. This second peak has been reported in other studies and may be attributed to a cohort effect or to a reactivation of latent viruses (14, 22). Mexican women seem to have the same age prevalence curve, regardless of the studied region. The second peak of prevalence has been observed worldwide, with the exception of Asia where rates continue to decrease (6). It is important to determine if the age-specific HPV prevalence is dependent on HPV type in order to begin to understand the factors involved in this distribution pattern. It has been reported that women with at least seven full-term pregnancies have a 3- to 5-fold increased risk for development of CC compared with nulliparous women. However, in this population the number of pregnancies showed no association with cervical lesion. Risk factors associated with CC in certain populations may not be important in other populations.

Our data contribute to the knowledge of HPV epidemiology and support the proposal of including HPV diagnosis in the screening programs to prevent CC. This acquires importance because of the recent introduction of the HPV vaccine in our country. The information can help in the future to monitor the impact of vaccination programs on the prevalence of HPV and CC in a specific population.
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